Skip to content

Sign in Start free

Create your free account

Loading your page…

We care for the people who care.

No ads. No selling of your data. No third-party trackers.

Apps

Prognia
Ward
Suture
Osler

Library

Guidelines
Medicines
Articles
Calculators
Explore decks
Institutions
Pharmaceutical companies
Blog

Prognia

About
Pricing
Contact

Support us

Founders Wall

© 2026 Prognia · Amsterdam, the NetherlandsPrivacy TermsExchangeRate-API

Loading…

Medicines
Netherlands
Lutetium(177 lu)oxodotreotide

CBG-MEB 2017

Lutetium(177 lu)oxodotreotide

Lutathera 370 MBq/ml, oplossing voor infusie

Oplossing voor infusieNetherlandsAuthorisedAuthorised 26 Sept 2017

Product informationAsk Osler about it

On this page

In other countries
Documents
Sources and licences

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

LutatheraEuropean UnionAuthorised

LutatheraCanada · 370 MBq / ML · Solution · Novartis Pharmaceuticals Canada INCSame brand
LutatheraEuropean Union · Advanced Accelerator ApplicationsSame brand
LutatheraCroatiaSame brand
LutatheraItaly · Soluzione per infusione · Novartis Europharm LimitedSame brand
Lutathera Solution for Infusion 370 MBQ/MLSingapore · 370 Mbq/ml · injection, solution (radiopharmaceutical) · Novartis (Singapore) Pte LTDSame brand

Documents

The official texts, at the regulator.

More with the same substance on this register

EndolucinBeta 40 GBq/mL, radiofarmaceutische precursor, oplossingLutetium(177 lu)oxodotreotide · Radiofarmaceutische uitgangsstofNetherlands
Ilumira 37 GBq/ml radiofarmaceutische uitgangsstof, oplossing

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Summary of product characteristicsCBG-MEB

Register entryCBG-MEB

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim · Added 8 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Lutetium(177 lu)oxodotreotide
Dosage form: Oplossing voor infusie
Route: Intraveneus gebruik
Register: Netherlands (CBG-MEB)
Status: Authorised
Status in the register: Ingeschreven
Authorised: 26 Sept 2017
Registration: EU/1/17/1226
Marketing authorisation holder: Novartis Europharm Limited
ATC code: V10XX04
Group: Various
Procedure: EU centralised
Supply: Uitsluitend recept
EMA product number: EMEA/H/C/004123
EU number: EU/1/17/1226

Lutetium(177 lu)oxodotreotide · Radiofarmaceutische uitgangsstof

🇳🇱Netherlands

CBG-MEBLutetium (177Lu)-chloride Billev 51,8 GBq/ml radiofarmaceutische precursor, oplossingLutetium(177 lu)oxodotreotide · Radiofarmaceutische uitgangsstof🇳🇱Netherlands

CBG-MEBMonlutenca 40 GBq/ml radiofarmaceutische precursor, oplossingLutetium(177 lu)oxodotreotide · Radiofarmaceutische uitgangsstof🇳🇱Netherlands

CBG-MEBTheralugand 40 GBq/ml radiofarmaceutische uitgangsstof, oplossingLutetium(177 lu)oxodotreotide · Radiofarmaceutische uitgangsstof🇳🇱Netherlands